It is important to determine whether breast cells overexpressing PGRMC1 are more likely to develop into tumor cells in women receiving E2/NET hormone therapy, which would help to determine the risks of MHT in relation to breast cancer. Here, PGRMC1 is linked to breast carcinoma.